DanCann Pharma A/S
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company's development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 Cann… Read more
DanCann Pharma A/S (DCPXF) - Net Assets
Latest net assets as of December 2024: $13.57 Million USD
Based on the latest financial reports, DanCann Pharma A/S (DCPXF) has net assets worth $13.57 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.06 Million) and total liabilities ($1.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.57 Million |
| % of Total Assets | 90.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | -69.38% |
| 10-Year Change | N/A |
| Growth Volatility | 49.38 |
DanCann Pharma A/S - Net Assets Trend (2019–2024)
This chart illustrates how DanCann Pharma A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DanCann Pharma A/S (2019–2024)
The table below shows the annual net assets of DanCann Pharma A/S from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $13.57 Million | +42.76% |
| 2023-09-30 | $9.51 Million | -84.86% |
| 2022-09-30 | $62.79 Million | +17.66% |
| 2021-09-30 | $53.37 Million | +20.41% |
| 2020-09-30 | $44.33 Million | +7188.96% |
| 2019-09-30 | $-625.27K | -- |
Equity Component Analysis
This analysis shows how different components contribute to DanCann Pharma A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1088373100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $25.08 Million | 184.81% |
| Total Equity | $13.57 Million | 100.00% |
DanCann Pharma A/S Competitors by Market Cap
The table below lists competitors of DanCann Pharma A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Elementos Ltd
AU:ELT
|
$39.89 Million |
|
AB Science S.A
PINK:ABSCF
|
$39.89 Million |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
$39.90 Million |
|
Nanexa AB
ST:NANEXA
|
$39.92 Million |
|
Clipper Realty Inc
NYSE:CLPR
|
$39.85 Million |
|
Black Mammoth Metals Corporation
PINK:LQRCF
|
$39.81 Million |
|
SBF AG
F:CY1K
|
$39.81 Million |
|
Bon Fame Co Ltd
TWO:8433
|
$39.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DanCann Pharma A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,506,000 to 13,571,000, a change of 4,065,000 (42.8%).
- Net loss of 7,929,000 reduced equity.
- New share issuances of 14,881,000 increased equity.
- Other factors decreased equity by 2,887,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.93 Million | -58.43% |
| Share Issuances | $14.88 Million | +109.65% |
| Other Changes | $-2.89 Million | -21.27% |
| Total Change | $- | 42.76% |
Book Value vs Market Value Analysis
This analysis compares DanCann Pharma A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.94x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | $-0.03 | $10.00 | x |
| 2020-09-30 | $2.14 | $10.00 | x |
| 2021-09-30 | $1.76 | $10.00 | x |
| 2022-09-30 | $0.97 | $10.00 | x |
| 2023-09-30 | $19.27 | $10.00 | x |
| 2024-09-30 | $3.40 | $10.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DanCann Pharma A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -102.13%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.11x
- Recent ROE (-58.43%) is above the historical average (-128.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-437.29K |
| 2020 | -9.60% | 0.00% | 0.00x | 1.12x | $-8.69 Million |
| 2021 | -22.02% | -1344.39% | 0.01x | 1.29x | $-17.09 Million |
| 2022 | -25.58% | -279.42% | 0.08x | 1.17x | $-22.34 Million |
| 2023 | -654.94% | -1025.01% | 0.35x | 1.83x | $-63.21 Million |
| 2024 | -58.43% | -102.13% | 0.52x | 1.11x | $-9.29 Million |
Industry Comparison
This section compares DanCann Pharma A/S's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DanCann Pharma A/S (DCPXF) | $13.57 Million | 0.00% | 0.11x | $39.87 Million |
| Abcam plc (ABCZF) | $726.90 Million | -1.17% | 0.45x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $11.42 Million | 85.41% | 3.81x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.25 Million |
| Adamas Trust, Inc. (ADAMG) | $2.43 Billion | 7.94% | 1.33x | $2.09 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $33.92 Million | -162.39% | 2.67x | $10.06 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $5.32 Million | -457.58% | 45.29x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $4.04 Billion | 10.04% | 0.29x | $112.87K |
| Alvotech Warrant (ALVOW) | $-564.42 Million | 0.00% | 0.00x | $35.01 Million |